|[June 16, 2014]
StemSynergy Therapeutics Invited to Present at the NIH SBIR/STTR Innovation Zone at the 2014 BIO International Biotechnology Conference
MIAMI --(Business Wire)--
StemSynergy Therapeutics Inc. is pleased to announce that it has been
selected to participate in the NIH SBIR/STTR Innovation zone at the 2014
BIO International Biotechnology Conference. This is an exciting
opportunity for SSTI to showcase our drug discovery platform and lead
compounds targeting the WNT pathway.
"The Innovation Zone offers an inside look at some of America's most
promising biomedical technology firms strategically positioned and ready
for investor and partnering engagement, said Lenka Fedorkova, PhD,
program manager for NIH
SBIR/STTR programs. "We are committed to supporting our companies
along their path to commercialization and are excited to partner with
BIO to showcase the next generation of health care market solutions at
BIO's Innovation Zone."
StemSynergy Therapeutics is a biopharmaceutical company focused on the
discovery and development of novel small-molecule drugs that target
developmental pathways fundamental to cancer. Our mission is to optimize
efficacy against developmental pathways that drive cancer stem cells,
such as the WNT, Sonic Hedgehog and Notch signaling pathways.
[ Back To TMCnet.com's Homepage ]